Belmore Neidrauer was recognized for acting on behalf of Janssen in the LMG Life Sciences Patent Impact Case of the Year Teva v Janssen (2023 FCA 68) at the 2023 LMG Life Sciences Americas Awards.
Our firm is ranked Tier 1 for National and Regional (Toronto) expertise in Intellectual Property Law.
The results reflect performance and reputation and shows “how leading firms combine client service, leadership and strategic insight to define Canada’s legal standards”.
On October 9, 2025, Belmore Neidrauer represented Janssen in the Supreme Court of Canada in a case dealing with the law on patentable subject matter (method of medical treatment law).
Belmore Neidrauer is pleased to be recognized in the LMG Life Sciences firm and attorney rankings covering the Americas!
The firm is ranked as recommended in Patent Litigation (Branded).
